期刊文献+

HPLC-荧光检测法测定大鼠血浆伊伐布雷定浓度 被引量:6

Determination of Ivabradine in Rat Plasma by a Validated HPLC with Fluorescence Detection
原文传递
导出
摘要 目的建立测定血浆中伊伐布雷定浓度的高效液相-荧光(FLU)测定方法,用于临床血浆伊伐布雷定浓度的测定。方法血浆样品经VarianC2柱固相萃取后采用HPLC-FLU法在Kromasil@C18柱分离,流动相采用乙腈-10mmol·L^-1磷酸二氢钾(含0.3%10mmol·L^-1盐酸)(28:72),流速为1mL·min^-1,柱温为25℃,荧光检测波长:λ1=328nm,λ2=283nm。结果内源性杂质不干扰测定,伊伐布雷定在0.5—50μg·L^-1内线性良好(r=0.9996),最低定量限为0.5μg·L^-1。萃取回收率为78.74%~90.77%(n=5),批内和批问精密度(RSD%)分别为2.53~6.33(n=6)和6.38~8.91(n=3)。结论建立的固相萃取-HPLC—FLU方法简便、灵敏、准确、所需血浆量少,可以用于临床血药浓度测定。 OBJECTIVE To develop a HPLC-FLU method for the determination of ivabradine in plasma. METHODS The plasma samples with Varian C2 solid-extraction pretreatment were separated on a Kromasil C18 column, using acetonitrile-10 mmol ·L^-1 KH2PO4 (containing 0. 3% 10 mol · L^-1 hydroehloride) (28: 72) as the mobile phase. The flow rate was 1.0 mL · min^-1 at room temperature. Detection was carried out at hi = 328 nm and k2 = 283 rim. RESULTS The method was linear for ivabradine in the range of 0. 5 - 50 μg · L ^- 1. The correlation coefficient was 0. 999 6 and the LLOQ was 0. 5 μg · L ^- 1. The extraction recoveries were in the range of 78.74% - 90. 77% ( n = 5 ). The intra-day and inter-day precisions ( RSD% ) were 2, 53 - 6. 33 ( n = 6) and 6. 38 - 8. 91 ( n = 3). CONCLUSION The HPLC-FLU method was simple, sensitive and accurate. It was suitable for the determination of ivabradine in plasma.
出处 《中国药学杂志》 CAS CSCD 北大核心 2010年第4期307-310,共4页 Chinese Pharmaceutical Journal
基金 科技部"国家科技重大新药创制"专项资助(2008ZX09312-010)
关键词 伊伐布雷定 荧光 固相萃取 血浆 ivabradine fluorescence detection solid-extraction plasma
  • 相关文献

参考文献5

  • 1JEAN-CLAUDE T. Clinical efficacy of ivabradine [ J ]. Heart Drug, 2005, 5 (1): 25-28.
  • 2FOX K, FORD I, STEG P G, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo-cantrolled trial[J]. Lancet, 2008, 372(9641) : 807-816.
  • 3KLIPPERT P, JEANNIOT J P, POLYE S, et al. Determination of ivabradine and its N-demethylated metabalite in human plasma and urine, and in rat and dog plasma by a validated high performance liquid chromatographic method with fluorescence detection[ J]. J Chromatogr B. 1998.719(1-2) : 125-133.
  • 4FRANCOIS-BOUCHARD M, SIMONIN G, BOSSANT M J, et aL Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography tandem mass spectrometry [ J ]. J Chromatogr B, 2000,745 (2) :261-269.
  • 5RAGUENEAU l, LAVEILLE C, JOCHEMSEN R, et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers[ J]. Clin Pharmacol Ther , 1998,64(2) :192-203.

同被引文献22

  • 1高照,李法琦.伊伐布雷定减慢心率的研究现状[J].心血管病学进展,2009,30(6):995-998. 被引量:11
  • 2段徐,凌峰.I_f抑制剂与心血管疾病[J].国外医学(内科学分册),2006,33(8):323-325. 被引量:2
  • 3TARD IF J C.Clinical efficacy of ivabradine[J].Heart Drug,2005,5(1):25-28.
  • 4FOXK,FORD I,STEG P G,et al.Ivabradine for patients with stable coron aryartery disesse and left-ventricular systolic dysfunction(BEAUTIFUL):a randomised,doubleblind,placebo-controlled trial[J].Lancet,2008,372(9641):807-816.
  • 5.中国药典[S]二部[M].,2005年版.844.
  • 6梁可,张浩,曹蕾,朱尔佳,谭载友.第一个窦房结I_f电流选择特异性抑制剂——盐酸伊伐布雷定的研究进展[J].中国处方药,2007,6(9):18-19. 被引量:7
  • 7国家药典委员会.中国药典2010年版[S].二部.北京:中国医药科技出版社,2010:179-180.
  • 8希恩.C.斯威曼,马丁代尔药物大典[M].35版.北京:化学工业出版社,2008:1034-1035.
  • 9Zaky H,Elzein H,Alsheikh-Ali AA,et al.Short-term effects of ivabradine in patients with chronic stable is chemic heart disease[J].Heart Views,2013,14(2):53-55.
  • 10Ragueneau I,Laveille C,Jochemsen R,et al.Pharma-cokinetic -pharmacodynamic modeling of the effects of ivabradine,a direct sinus node inhibitor,on heart ratein healthy volunteers[J].Clin Pharmacol Ther,1998,64(2):192-203.

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部